Primary adenoid cystic carcinoma of the breast: case report and review of the literature

Muslimani, Alaa; Ahluwalia, Manmeet; Clark, Crystal T.; Daw, Hamed

doi:10.1186/1477-7800-3-17

Cited by 32 publications

(12 citation statements)

References 15 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Supporting findings in previous reports [15,17-21,27,29,31,35-38,48,50,52,54-57], the majority of breast-ACC in the SEER Program was ER-negative/PR-negative; however, hormone receptor-positive tumors have also been described in a minority of cases [22,23,25,32,34,42,58]. Although information on HER-2-neu is not available in the SEER Program, other series have uniformly reported HER-2-neu-negative status in breast-ACC [18,20,21,23,31,34,37,38,42,50,52,55,56].…”

Section: Discussionsupporting

confidence: 91%

“…In contrast to what might be expected with ER-negative, PR-negative, HER-2-neu-negative (triple-negative) breast cancers, the majority of cases of breast-ACC in the SEER Program rarely involved regional LN and most were associated with excellent survival. These findings support clinical reports that largely [12,20-25,29,31,32,34-38,41,42,48,50-52,55,56], but not exclusively [21-24,34,42,49], describe absence of LN involvement and excellent survival [22,24,25]. Metastatic breast-ACC has been rarely reported at initial diagnosis [22], and only one case was observed in the SEER Program over a 30-year period.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study

et al. 2010

View full text Add to dashboard Cite

IntroductionAdenoid cystic carcinoma of the breast (breast-ACC) is a rare and special type of basal-like tumor for which scant population-based descriptive data exist. We sought to provide new population-based information on breast-ACC incidence, relative survival, and associated cancer risk in the United States.MethodsUsing data from the Surveillance, Epidemiology and End Results Program, we calculated age-adjusted incidence rates (IRs), IR ratios (IRRs), and relative survival for breast-ACC, and standardized incidence ratios (SIRs) for other cancers.ResultsOverall 338 women (IR = 0.92/1 million person-years) were diagnosed with breast-ACC during 1977 to 2006. Blacks had 39% lower IRs than Whites (IRR = 0.61, 95% confidence interval = 0.37 to 0.96), and IRs remained constant over the 30-year period. Ninety-five percent of cases presented with localized stage (n = 320; IR = 0.87), and the highest IRs were observed for estrogen receptor (ER)-negative/progesterone receptor (PR)-negative tumors (IR = 0.56). Like other typically ER-negative tumors, age-specific IRs increased until midlife and then plateaued. Five-year, 10-year, and 15-year relative survival was 98.1%, 94.9%, and 91.4%, respectively. The risk of female breast cancer was not increased following (SIR = 0.89, 95% confidence interval = 0.43 to 1.64) or preceding (SIR = 0.71, 95% confidence interval = 0.28 to 1.46) breast-ACC. Similarly, no association was observed for breast-ACC and risk of all other cancers combined, solid tumors, or lymphohematopoietic malignancies.ConclusionsBreast-ACC among women is characterized by ER-negative/PR-negative expression, rare regional lymph node involvement, a favorable prognosis with excellent survival, and absence of associated cancers. These findings reinforce the importance of tailored treatments for breast-ACC and lend credence to the apparent heterogeneity of basal-like breast cancers.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 90%

Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Generally, they occur in female patients with a median age of 58 to 64 years. Therefore, there are limited guidelines for treatment and diagnosis, and they are based on guidelines used for ACC of the breast in females (1)(2)(3)(4)(5)(6). In the present study, we reported a rare case of ACC of the breast in a 42 year-old man.…”

Section: Introductionmentioning

confidence: 70%

Male Adenoid Cystic Carcinoma of Breast

2017

View full text Add to dashboard Cite

Introduction: Adenoid cystic carcinoma (ACC) of the breast is a rare tumor, especially observed in males. Case Presentation: We presented a 42-year-old man, initially diagnosed with small cell carcinoma (SCC) by core needle biopsy. He underwent breast modified radical mastectomy (MRM) and axillary lymph node dissection; his final histopathological diagnosis was ACC. After surgery, although the patient was recommended to have post-operative chemo-radiotherapy, he did not comply. The patient is on follow-up for more than a year with no recurrence until now. Conclusions: ACC of the breast is a rare malignancy with excellent prognosis and favorable tumor biology. It could be mistaken with triple negative breast cancer, ductal carcinoma in situ (DCIC), and small cell carcinoma.

show abstract

“…ACC is a rare malignancy of exocrine glands defined by the presence of a dual population of cells, and identical tumors can also arise from the breast. The unique characteristics of breast-ACC include a lack of expression of the estrogen receptor (ER), the progesterone receptor (PR), and HER2 and a basal-like phenotype in transcriptomic analysis [ 1 , 4 , 5 ]. However, HR+ breast-ACC has been reported [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database

Chen

Wang

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Adenoid cystic carcinoma of the breast (breast-ACC) is a rare and indolent tumor with a good prognosis despite its triple-negative status. However, we observed different outcomes in the present study. Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, we enrolled a total of 89,937 eligible patients with an estimated 86 breast-ACC cases and 89,851 invasive ductal carcinoma (IDC) patients. In our study, breast-ACC among women presented with a higher proportion of triple-negative breast cancer (TNBC), which was more likely to feature well-differentiated tumors, rare regional lymph node involvement and greater application of breast-conserving surgery (BCS). Kaplan-Meier analysis revealed that patients with breast-ACC and breast-IDC patients had similar breast cancer-specific survival (BCSS) and overall survival (OS). Moreover, using the propensity score matching method, no significant difference in survival was observed in matched pairs of breast-ACC and breast-IDC patients. Additionally, BCSS and OS did not differ significantly between TNBC-ACC and TNBC-IDC after matching patients for age, tumor size, and nodal status. Further subgroup analysis of molecular subtype indicated improved survival in breast-ACC patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/Her2-) tumors compared to IDC patients with HR+/Her2- tumors. However, the survival of ACC-TNBC and IDC-TNBC patients was similar. In conclusion, ACCs have an indolent clinical course and result in similar outcomes compared to IDC. Understanding these clinical characteristics and outcomes will endow doctors with evidence to provide the same intensive treatment for ACC-TNBC as for IDC-TNBC and lead to more individualized and tailored therapies for breast-ACC patients.

show abstract

Primary adenoid cystic carcinoma of the breast: case report and review of the literature

Cited by 32 publications

References 15 publications

Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study

Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study

Male Adenoid Cystic Carcinoma of Breast

Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database

Contact Info

Product

Resources

About